RO5068760
RO5068760 is a potent, orally active and selective non-ATP-competitive MEK1/2 inhibitor with an IC50 of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research[1].
Product Specifications
CAS Number
947182-25-4
UNSPSC
12352005
Target
Apoptosis; CDK; ERK; MEK; p38 MAPK; PARP
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway; Stem Cell/Wnt
Field of Research
Cancer
Smiles
C[C@@H](C1=CC=CC=C1)[C@H](N2C([C@@H](C3=CC=C(C=C3)OC[C@H](O)CO)NC2=O)=O)C(NC4=C(C=C(C=C4)I)F)=O
Molecular Formula
C28H27FIN3O6
Molecular Weight
647.43
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MEK1; MEK2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human CD140a/PDGFRA Protein, C-His (Active)